Explore Pathway Governance at a Health System Without Recommending Placement

A pharmacy director who asks where a product should sit on the internal pathway is not asking for your opinion on placement. The director is describing a governance process, and the fastest way to lose credibility with a health system is to treat that question as an opening to sell. A market access manager who understands the difference can still be useful in that room. You can clarify how the pathway review works, what evidence standard the committee applies, and who signs off on the final decision, all without stepping into a clinical judgment that is not yours to make.

Why This Conversation Goes Wrong

Most managers get into trouble here for a simple reason. They are trained to answer questions directly and to move a conversation toward a decision. A pharmacy director asking about placement sounds like an invitation to do exactly that. It is not. Health systems separate commercial input from clinical decision making on purpose, and a pathway committee that includes your recommendation in its notes has created a problem for itself and for you.

The pressure is real. Directors are often direct, sometimes blunt, and they may genuinely want your read on where a product fits relative to competitors. Silence feels evasive. A vague non answer feels like you are hiding something. The instinct to fill that gap with a helpful sounding opinion is strong, and that is exactly the moment where a manager crosses from access support into clinical advocacy.

There is also a subtler failure mode. Some managers avoid the recommendation trap but overcorrect into being unhelpful. They repeat that they cannot comment on placement and offer nothing else, which reads as evasive and damages the relationship just as much as overstepping does. The goal is not to say less. It is to redirect the conversation toward what you can actually do, which is usually more valuable to the director than a recommendation would have been anyway.

How to Prepare Before You Walk In

Before any meeting where pathway placement might come up, find out how this specific health system runs its review. Pathway governance varies a lot from one system to another. Some route decisions through a single pharmacy and therapeutics committee. Others split authority between a clinical governance lead and a disease specific tumor board or specialty panel. Know which model applies to the account you are meeting, and know it before the director brings it up.

Write down three things ahead of the conversation. First, who owns the final placement decision at this system, by title if you can get it. Second, what evidence format the committee expects, whether that is a formal dossier, a short summary with citations, or a presentation slot. Third, what your own approved resources cover and where they stop. If a director asks a question that drifts into clinical interpretation of trial data, you need to already know which medical affairs contact or approved clinical resource can take that question, so you are not scrambling to find one mid meeting.

It helps to review how a similar conversation plays out on the payer side. The approach in Prepare for a Payer Evidence Request applies here too. Get your materials organized before the ask arrives, not after.

What to Say When the Director Pushes for a Recommendation

Picture a fictional meeting. The pharmacy director leans in and says, "You know this product better than anyone in this room. Just tell us, where would you put it on the pathway."

You respond, "That call belongs to your committee, and I would rather help your review move faster than guess at an answer that is not mine to give. What I can do is make sure your reviewers have the evidence they need, in the format they expect, before your next meeting. Who is chairing that review, and what does the committee usually want to see?"

The director says, "Our pharmacy committee runs it, and Dr. Alvarez chairs clinical governance. They will want published data and any comparative outcomes you have, with citations."

You answer, "I can get that packaged and sent to both of them this week. If Dr. Alvarez has questions that go beyond the published data, I will loop in our medical science liaison directly, since that conversation should come from someone with clinical authority. Does your committee have a date locked in yet?"

Notice what happened in that exchange. You did not dodge the question and you did not answer it either. You gave the director something more useful than a recommendation, a clear next step with names and a deadline attached. That is the trade you want to make every time this comes up.

Mistakes That Undermine Your Credibility

A few patterns show up again and again in these conversations, and each one costs you something.

1. Answering the placement question directly, even with hedging language like "if it were me" or "off the record." Committees write minutes. A recommendation attributed to you, even informally, can surface later and put both you and the system in an awkward position.
2. Going silent instead of redirecting. Refusing to engage without offering a path forward makes you look unprepared rather than compliant.
3. Promising clinical interpretation you are not qualified to give. If a director wants your read on how a trial's outcomes compare to a competitor's, that question belongs with medical affairs, not with you, no matter how well you know the data.
4. Failing to follow up with actual materials after the meeting. Redirecting a director toward a process only works if you deliver on the process. A manager who says "I will get the committee what they need" and then goes quiet has broken the trade they just made.
5. Skipping the stakeholder mapping step. If you leave the meeting without a name, a role, and a deadline, you have gathered goodwill but no plan.

How to Practice and Score This Conversation

This exchange is hard to get right the first time in a real meeting, because the pull toward answering directly is strong and the redirect has to sound natural, not scripted. Rehearsing it against a realistic counterpart, the way DealSpeak sets up, lets you find your own phrasing before a director ever asks the question live. A manager coaching someone through this should score the call on whether the redirect is clean, whether the manager names a specific committee owner and deadline, and whether any clinical question gets handed off rather than answered in the room.

The same discipline applies to related meetings your team will hit. If you are also mapping out who needs to be in the room for a payer review, Build the Right Stakeholder Plan for a Payer Review walks through that groundwork. And if pathway governance is a recurring theme in your accounts, the full set of Pharmaceuticals practice conversations covers other moments where the line between access support and clinical advocacy gets tested.

After the meeting, write the stakeholder map while it is still fresh. Note the decision owner, the evidence reviewer, the deadline, and exactly what follow up you are permitted to send. That document is what turns a conversation you handled well into a result the account actually remembers.

Handled this way, a pathway governance question stops being a trap and becomes a chance to show a health system that you understand how their process works. That is worth more to the relationship than any opinion on placement would have been.